Whole body MRI is highly accurate in the early detection of breast cancer metastases

May 6, 2010

Whole body magnetic resonance imaging (MRI) should be the imaging modality of choice for the detection of breast cancer metastases (when the cancer has spread beyond the breast) as it is highly accurate and can detect bone metastases while a patient is still asymptomatic (shows no symptoms), according to a study to be presented at the ARRS 2010 Annual Meeting in San Diego, CA.

Whole body MRI is a noninvasive medical test that helps physicians diagnose and treat . Breast cancer cells commonly spread to the bones, lungs, liver, or brain. Metastatic breast cancer tumors may be found before or at the same time as the primary tumor, or months and even years later.

"It is important that we detect metastases early in order to ensure the patient is getting the appropriate treatment. This study shows that whole body MRI can accomplish this task and is ready to be used for this indication," said Joshita Singh, MD, lead author of the study.

Besides MRI, other imaging modalities commonly used to detect breast cancer metastases include positron emission tomography - computed tomography (PET/CT), chest X-rays, bone scans, and ultrasound of the abdomen and pelvis.

The study, performed at Deenanath Mangeshkar Hospital and Research Center in Pune, India, included 99 patients with known breast cancer who were evaluated for metastases using whole body MRI. "Of the 99 patients, MRI accurately revealed that 47 patients were positive for metastases while 52 were negative. Of those patients who were positive for metastases, whole body MRI frequently detected earlier when the patient was still asymptomatic," said Singh.

"As our study suggests, whole body MRI is an effective tool for the detection of metastases and unlike other procedures commonly used in this role, it emits no radiation. We highly recommend that whole body MRI be the imaging modality of choice for the detection of metastases in patients with breast cancer," she said.

Related Stories

Recommended for you

Tracking how multiple myeloma evolves by sequencing DNA in the blood

December 10, 2017
Although people with multiple myeloma usually respond well to treatment, the blood cancer generally keeps coming back. Following genetic changes in how the disease evolves over time will help to understand the disease and, ...

Landmark CAR-T cancer study published

December 10, 2017
Loyola University Medical Center is the only Chicago center that participated in the pivotal clinical trial of a groundbreaking cancer treatment that genetically engineers a patient's immune system to attack cancer cells.

Study finds emojis promising tool for tracking cancer patients' quality of life

December 10, 2017
In findings presented to the American Society of Hematology, Mayo Clinic researchers found that using emojis instead of traditional emotional scales were helpful in assessing patients' physical, emotional and overall quality ...

Study explores use of checkpoint inhibitors after relapse from donor stem cell transplant

December 10, 2017
Immunotherapy agents known as checkpoint inhibitors have shown considerable promise in patients with hematologic cancers who relapse after a transplant with donor stem cells. Preliminary results from the first clinical trial ...

Blood test may help predict which breast cancers will recur

December 8, 2017
A blood test five years after breast cancer treatment helped identify some women who were more likely to relapse, long before a lump or other signs appeared, a preliminary study found.

Alcohol-abuse drug Antabuse kills cancer cells

December 8, 2017
A new study in Nature by an international team including researchers from Karolinska Institutet, reports that the alcohol-abuse drug Antabuse is effective against cancer. The study also identifies a potential mechanism of ...

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

singhavi
not rated yet May 06, 2010
During the course of this latest study, researchers worked on data taken from the large WHI or Women Health Initiative. They uncovered that the levels of marker EGFR (epidermal growth factor receptor) could shoot up in the blood samples of females before even seventeen months of their breast cancer diagnosis. Epidermal growth factor receptor is a marker that plays a vital role in the development and metastasis of breast cancer cells.

To read more :

http://www.cancer...sis.html
http://www.cancer...ion.html

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.